AGL (agilon health, inc.)

Insider Trading Activity

Every open-market purchase and sale reported by AGL officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

Form 4 Filings
50
most recent
Open-Market Buys
2
code P
Sales
0
code S
Reporting Insiders
19
current holders
AGL — Recent Form 4 Transactions (latest 2026-08-18)
FiledInsiderRole TypeSharesValue
2026-08-18 Timothy Gertsch Chief Accounting Officer F
2026-08-04 Denise Zamore Chief Legal Officer F
2026-07-02 Jeffrey A. Schwaneke Chief Financial Officer F
2026-06-05 Denise Zamore Chief Legal Officer F
2026-06-04 John William Wulf Director A
2026-06-04 Silvana Battaglia Director A
2026-06-04 Karen McLoughlin Director A
2026-06-04 DIANA MCKENZIE Director A
2026-06-04 RONALD A WILLIAMS Director A
2026-06-04 Sharad Mansukani Director A
2026-05-27 Timothy Gertsch Chief Accounting Officer F
2026-05-11 Timothy Patrick O'Rourke CEO & President A
2026-04-16 Timothy Gertsch Chief Accounting Officer F
2026-04-16 Benjamin Shaker Chief Markets Officer F
2026-04-16 Denise Zamore Chief Legal Officer F
2026-04-16 Girish Venkatachaliah Chief Technology Officer F
2026-04-03 Jeffrey A. Schwaneke Chief Financial Officer MIXED
2026-04-03 Girish Venkatachaliah Chief Technology Officer MIXED
2026-04-03 Denise Zamore Chief Legal Officer MIXED
2026-04-03 Timothy Gertsch Chief Accounting Officer MIXED
2026-04-03 Benjamin Shaker Chief Markets Officer MIXED
2026-03-11 Denise Zamore Chief Legal Officer MIXED
2026-03-11 Benjamin Shaker Chief Markets Officer MIXED
2026-03-11 Girish Venkatachaliah Chief Technology Officer MIXED
2026-03-03 Benjamin Shaker Chief Markets Officer Buy
2026-01-30 John William Wulf Director Buy
2026-01-13 Jeffrey A. Schwaneke Chief Financial Officer A
2025-08-19 Timothy Gertsch Chief Accounting Officer F
2025-08-05 Denise Zamore Chief Legal Officer F
2025-07-03 Jeffrey A. Schwaneke Chief Financial Officer F
2025-05-30 RONALD A WILLIAMS Director A
2025-05-30 Karen McLoughlin Director A
2025-05-30 DIANA MCKENZIE Director A
2025-05-30 Jeffrey A. Schwaneke Chief Financial Officer F
2025-05-30 Silvana Battaglia Director A
2025-05-30 Sharad Mansukani Director A
2025-05-30 John William Wulf Director A
2025-05-28 Timothy Gertsch Chief Accounting Officer F
2025-04-16 Timothy Gertsch Chief Accounting Officer F
2025-04-16 Steven Sell CEO & President F
2025-04-16 Girish Venkatachaliah Chief Technology Officer F
2025-04-16 Benjamin Shaker Chief Markets Officer F
2025-04-16 Denise Zamore Chief Legal Officer F
2025-04-03 Timothy Gertsch Chief Accounting Officer A
2025-04-03 Benjamin Shaker Chief Markets Officer A
2025-04-03 Jeffrey A. Schwaneke Chief Financial Officer MIXED
2025-04-03 Steven Sell CEO & President A
2025-04-03 Girish Venkatachaliah Chief Technology Officer A
2025-04-03 Denise Zamore Chief Legal Officer A
2025-03-18 Girish Venkatachaliah Chief Technology Officer MIXED
AGL — Current Insider Holders
InsiderRole Shares HeldValue
10%+ Owner 8,237,952
10%+ Owner 4,000,000
CEO & President 320,000
Director 149,141
Chief Financial Officer 138,923
Chief Markets Officer 122,850
Chief Legal Officer 66,075
Director 56,242
CEO & President 38,659
Chief Technology Officer 38,566
Chief Strategy & Dev. Officer 19,921
Director 16,765
Chief Accounting Officer 14,152
Director 8,207
Director 7,926
Director 7,633
Director 6,525
Director 4,800
Chief Med. & Quality Officer 2,482
How to read Form 4 activity

Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.

Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.

Full filing history and per-insider positions are on the AGL quote page; the site-wide leaderboard is on the insider transactions hub.